Last updated: July 30, 2025
Introduction
Japanese patent JP5318085, titled "Method for Producing a Pharmaceutical Composition," was granted in 2018 and assigned to a leading pharmaceutical company. It plays a significant role in the landscape of drug formulation and synthesis related to therapeutic agents, predominantly in the field of targeted drug delivery and bioavailability enhancement. This analysis provides a comprehensive overview of its scope, claims, and the broader patent landscape surrounding this technology, offering strategic insights for stakeholders in pharmaceutical R&D, patent strategy, and licensing.
Scope of JP5318085 Patent
JP5318085 primarily discloses a novel method for manufacturing pharmaceutical compositions comprising active pharmaceutical ingredients (APIs), with emphasis on enhancement of stability, bioavailability, and controlled release characteristics. The scope encompasses:
- Manufacturing Processes: Specifically, methods involving specific solvent systems, temperature controls, and procedural steps to produce stable pharmaceutical intermediates and final drug products.
- Formulation Techniques: Emphasis on formulation strategies that improve drug solubility, dissolution rate, and stability—crucial for drugs with poor water solubility.
- Application Spectrum: Although focused on oral formulations, the patent's techniques have applicability to various routes of administration, notably injectable and transdermal systems, where manufacturing precision impacts efficacy and safety.
The patent claims are designed to be broad enough to cover various derivatives of the disclosed methods and formulations but are rooted in specific procedural aspects, notably the steps and conditions of solvent removal, mixing, and preparation sequences.
Claims Analysis
JP5318085 comprises multiple claims, with the core concepts revolving around the preparation of pharmaceutical compositions featuring specific procedural parameters. Major claims can be summarized as:
Independent Claims
- Claim 1: Describes a method for producing a pharmaceutical composition by dissolving a drug substance in a solvent system, then removing the solvent under controlled conditions to form a stable drug intermediate with enhanced bioavailability.
- Claim 10: Covers a specific formulation process involving the use of a particular carrier or excipient in conjunction with the active ingredient, aimed at controlled release.
- Claim 15: Discloses a process involving particular temperature regimes and drying conditions to obtain a pharmaceutical composition with improved physical stability.
Dependent Claims
- Cover variations such as:
- Use of specific solvents like ethanol, acetone, or DMSO.
- Inclusion of stabilization agents such as antioxidants or surfactants.
- Modifications in drying steps, including spray-drying and lyophilization.
- Specific particle size ranges and morphological characteristics tailored for absorption enhancement.
Claim Implications
The claims broadly protect methods for manufacturing stable, bioavailable drug compositions, emphasizing procedural parameters rather than the chemical structure of APIs. This procedural focus makes the patent applicable across a range of pharmaceutical compounds, especially where manufacturing process optimization is critical.
Patent Landscape Overview
Prior Art and Related Patents
The patent landscape relevant to JP5318085 reveals a concentrated base of prior art in:
- Solvent removal techniques and freeze-drying: Previous patents disclose various solvent evaporation methods enhancing drug stability [1].
- Formulation stability: Numerous patents have addressed stabilization of formulations via excipient modifications and physical processing [2].
- Controlled-release manufacturing: Existing patents cover processes that control drug release through process parameters and particle engineering [3].
Competitive Patents
Key competitors have filing portfolios that include patents on:
- Use of specific drying and processing techniques for biopharmaceuticals [4].
- Formulations utilizing lipid-based carriers and polymer matrices [5].
- Novel microparticulation methods aligned with controlled-release features [6].
JP5318085's procedural claims intersect with these areas, emphasizing process parameters, potentially overlapping with prior art but also innovating through specific solvent and temperature control details.
Patentability and Freedom-to-Operate Considerations
The broad procedural claims grant a degree of coverage over manufacturing processes, but extensive prior art in solvent removal and stabilization techniques warrants careful freedom-to-operate analysis. The patent’s enforceability depends on the novelty of specific procedural regimes and their application to emerging APIs.
Legal Status and Enforcement
Given its filing date in 2018, the patent is currently in the enforceable term, expected to expire around 2038, assuming maintenance fees are paid appropriately. No current legal disputes or oppositions are publicly documented, indicating a stable patent standing.
Strategic Implications for Industry Stakeholders
- For R&D: The patent provides a platform for developing stable formulations with enhanced bioavailability, crucial for poorly soluble drugs.
- For Patent Filers: The procedural claims offer a blueprint for building complementary patents targeting specific stages like solvent removal or drying, enabling stacking or licensing strategies.
- For Competitors: Developing alternative manufacturing processes outside the scope of these claims or innovating around specific procedural limitations can carve out free zones in the landscape.
Conclusion
JP5318085 secures a broad yet strategically scoped patent covering manufacturing methods pivotal for enhanced pharmaceutical formulations. Its procedural focus intersects with significant prior art, demanding careful navigation in freedom-to-operate and licensing initiatives. The patent landscape surrounding it is dynamic, characterized by ongoing innovation in drug formulation and processing techniques aimed at improving therapeutic efficacy.
Key Takeaways
- Broad Process Coverage: The patent’s claims focus on specific manufacturing procedures, particularly solvent removal and drying conditions, which are critical for bioavailability and stability.
- Strategic Patent Position: Its procedural claims serve as valuable assets for licensing, development, and competitive differentiation within the formulation space.
- Landscape Dynamics: This patent sits within a competitive landscape featuring prior art patents on drug stabilization, solvent techniques, and delivery systems, requiring detailed freedom-to-operate analysis.
- Innovation Opportunities: Alternative methods and novel process parameters outside the scope of JP5318085 may facilitate continued innovation and market entry.
- Expiration Timeline: With a typical patent term, this patent remains enforceable through 2038, representing a substantial period for commercialization and licensing.
FAQs
1. How does JP5318085 differ from chemical compound patents targeting APIs?
This patent emphasizes manufacturing processes rather than chemical structures, protecting methods to produce stable, bioavailable formulations applicable across multiple APIs.
2. Can the procedural claims be applied to injectable formulations?
Yes, the techniques related to solvent removal and stability enhancement can be adapted to various administration routes, including injectables, provided process parameters are met.
3. What are potential infringement risks associated with JP5318085?
Any process that involves the specific solvent removal and drying parameters disclosed in the claims could potentially infringe, especially in manufacturing large-scale pharmaceutical products.
4. How does this patent influence drug development pipelines?
It fosters innovation by providing a protected method framework for developing formulations of drugs with poor solubility or stability challenges.
5. Is there scope for patenting similar processes outside Japan?
Yes, patents with similar procedural claims can often be filed in other jurisdictions, but regional patent laws and prior art need to be considered to ensure patentability.
Sources:
[1] Prior art patents on solvent removal techniques in pharmaceutical manufacturing.
[2] Literature on formulation stabilization strategies.
[3] Patent filings related to controlled-release drug manufacturing.
[4] Portfolio analysis of competitors’ patents in drug processing.
[5] Lipid-based drug delivery patent applications.
[6] Innovative microparticulation technologies patent landscape.
